730 results on '"Ossenkoppele, Gert"'
Search Results
2. Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)
3. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study
4. Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial
5. Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia
6. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
7. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
8. Acute promyelocytic leukemia: long-term outcomes from the HARMONY project
9. Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
10. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
11. Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters
12. The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
13. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
14. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
15. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
16. Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both?
17. Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification
18. SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
19. Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations
20. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
21. IGFBP7 activates retinoid acid–induced responses in acute myeloid leukemia stem and progenitor cells
22. Two decades of targeted therapies in acute myeloid leukemia
23. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
24. EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
25. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
26. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
27. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
28. Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use
29. Challenges in the diagnosis and treatment of secondary acute myeloid leukemia
30. Can we incorporate MRD assessment into clinical practice in AML?
31. Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia
32. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia
33. Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands
34. AML-234 Prognostic Value of FLT3-ITD Residual Disease in Acute Myeloid Leukemia
35. Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?
36. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
37. Correction to: The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
38. CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia
39. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
40. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
41. Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting
42. Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
43. Establishing human leukemia xenograft mouse models by implanting human bone marrow–like scaffold-based niches
44. A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia
45. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis
46. Immunophenotyping for diagnosis and prognosis in MDS: Ready for general application?
47. How I treat the older patient with acute myeloid leukemia
48. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis
49. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial
50. MRD in AML: It is time to change the definition of remission
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.